GlassScriptPhysician profile
Greg T Flinders
NPI 1386971240
$2,721.89
in general payments reported to CMS, 2019-2025
29 companies · $14.41 in 2025
The $14.41 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,807 · 2022: $613 · 2023: $239 · 2024: $48.16 · 2025: $14.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.02 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $284.77 | 2021-2025 | Airsupra |
| Lilly USA, LLC | $175.60 | 2021-2022 | |
| Amgen INC. | $168.12 | 2021-2023 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $167.76 | 2021 | |
| Novo Nordisk INC | $157.98 | 2021-2023 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $154.66 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $144.53 | 2021-2022 | |
| Pfizer INC. | $128.66 | 2021-2022 | |
| Amarin Pharma, INC. | $123.68 | 2021 | |
| Biogen, INC. | $109.36 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $92.23 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.45 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.73 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $30.85 | 2021 | |
| Exact Sciences Corporation | $27.38 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $27.00 | 2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $22.90 | 2023 | Nexletol |
| Boston Scientific Corporation | $21.21 | 2023 | |
| Corium, LLC | $19.85 | 2023 | Azstarys |
| Eisai INC. | $19.71 | 2021 | |
| Kyowa Kirin, INC. | $19.11 | 2023 | Crysvita |
| Medicure Pharma INC. | $18.94 | 2021 | |
| Sumitomo Pharma America, INC. | $17.67 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.99 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2022 | |
| Genentech USA, INC. | $9.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Flinders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.